ClinicalTrials.gg
CompletedNCT05803811Updated Nov 10, 2026

Effect of Colon Delivered Vitamin B2 on Gut Microbiota and Related Health Biomarkers in Healthy Older Adults

An interventional study of Riboflavin in Quality of Life, sponsored by dsm-firmenich Switzerland AG. Completed at 1 site in Ireland. Open to participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by dsm-firmenich Switzerland AG (part of dsm-firmenich) · Not applicable, Interventional, and Basic science

How we know

Updated Nov 10, 2026Primary outcomes revisedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Study summary

The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)

02

Conditions studied

  • Quality of Life

Keywords

  • microbiota
  • vitaminB2
  • Riboflavin
  • ShortChain fatty acids
03

In context

Lead sponsor

dsm-firmenich Switzerland AG is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be willing and able to give written and to understand, to participate, and to comply with the clinical study requirements.
  2. Between 50 and 70 years of age.
  3. Has a of between 18.5 - 30 Kg/m2.
  4. Participants have had a stable body weight (≤5 % change) over the past 3-months.
  5. Is in general good health, as determined by interview and vital signs (blood pressure, heart rate, pulse) by the investigator.
  6. Willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements, and, within 4 weeks prior to the baseline visit, until the end of the study.
  7. Maintain current level of physical activity.
  8. Willing to consume the product daily for the duration of the study.
  9. Female participants in menopause for at least the last one year. -

Exclusion criteria

Exclusion Criteria:

  1. Are hypersensitive to any of the components of the test product.
  2. Has taken antibiotics within the previous 3 months prior to Baseline (Visit2)
  3. Is currently using systemic , systemic antibiotics, proton pump inhibitors, H2 blocker, antacid, metformin, or medication.
  4. Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder).
  5. Is a smoker or vaper.
  6. Vegetarian or vegan.
  7. Has made any major dietary changes in the past 3 months prior to Baseline (Visit 2).
  8. Planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.
  9. Has a currently active eating disorder.
  10. Has food allergies or other issues with foods that would preclude the intake of the study products, as determined by the study investigator.
  11. Is having a typical fibre intake >30 g fibre/day.
  12. Has an active gastrointestinal disorder or previous gastrointestinal surgery, which in the opinion of the investigator would impact the study outcomes.
  13. If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months to screening and agree to maintain the same dosage throughout the study.
  14. Has severe or uncontrolled type 2 diabetes, psychiatric disorder, gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes.
  15. Has a current or history of any gastrointestinal cancer
  16. Are severely immunocompromised ( positive, transplant patient, on anti-rejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy with the last year).
  17. Experiences alarm features such as weight loss, rectal bleeding, a recent change in bowel habit (\<3 months).
  18. Have a current malignant disease or any concomitant end-stage organ disease.
  19. Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
  20. Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.
  21. Participants who have undergone intensive skin treatments (e.g. laser treatment or skin related surgery) in the last 3 months.
  22. If taking any dietary supplements or medications known to affect skin health or other trial measures (resveratrol, ginkgo biloba, ginseng, fruit powder extracts and DHA).
  23. Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).

    -

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
348 participants (actual)

Study arms

  • Experimental
    Low dose

    Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

    Dietary Supplement: Riboflavin

  • Experimental
    Mid dose

    Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks

    Dietary Supplement: Riboflavin

  • Experimental
    high dose

    Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks

    Dietary Supplement: Riboflavin

  • Placebo comparator
    Placebo

    One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks

    Dietary Supplement: Riboflavin

Interventions

  • Dietary supplementRiboflavin

    Colon delivered vitamin B2 (Riboflavin) for 12 weeks

06

What researchers measure

Primary outcomes

  1. Faecal microbial composition

    Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12

    Time frame: from baseline to 12 weeks

Secondary outcomes

  1. Alpha diversity

    Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12.

    Time frame: from baseline to 12 weeks

  2. Beta diversity

    Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12

    Time frame: week 0 to week 12

  3. Faecal microbial metabolites fatty acid content at baseline and week 12

    Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12

    Time frame: from baseline to 12 weeks

  4. Acetate, Propionate and Butyrate

    Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12.

    Time frame: baseline and week 12

  5. Intestinal inflammation

    Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12

    Time frame: from baseline to 12 weeks

  6. Intestinal barrier integrity

    Oxidative stress level measured as free thiol content in blood at baseline and at week 12

    Time frame: from baseline to 12 weeks

  7. Oxidative stress in blood

    Oxidative stress level measured as free thiol content in blood at baseline and at week 12

    Time frame: from baseline to 12 weeks

  8. Inflammatory status in blood

    Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12.

    Time frame: from baseline to 12 weeks

  9. Gastrointestinal symptoms

    Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12.

    Time frame: from baseline to 12 weeks

  10. health-related quality of life

    Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12. The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase.

    Time frame: from baseline to 12 weeks

  11. Stool consistency

    Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12). Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass \[classified as severe constipation\]; Type 7 = watery, entirely liquid stool \[classified as severe diarrhea\]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively.

    Time frame: from baseline to 12 weeks

  12. Stool frequency

    Stool frequency, as reported in the daily eDiary app (at baseline and week 12).

    Time frame: from baseline to 12 weeks

  13. Systemic vitamin status

    The concentration of B vitamins in blood at baseline

    Time frame: from baseline to 12 weeks

  14. Faecal physiological pH and redox

    Faecal physiological parameters measured as pH and redox potential at baseline and at week 12.

    Time frame: from baseline to 12 weeks

  15. Faecal microbial composition at week 4

    Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4.

    Time frame: from baseline to 4 weeks

  16. Alpha diversity at week 4

    Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4.

    Time frame: baseline to Week 4.

  17. Beta diversity at week 4

    Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4

    Time frame: week 0 to week 4

  18. Microbial metabolites at week 4

    Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4.

    Time frame: from baseline to 4 weeks

  19. Acetate, Propionate and Butyrate at week 4

    Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4.

    Time frame: week 0 to week 4

Other outcomes

  1. Skin barrier integrity

    Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12.

    Time frame: from baseline to 12 weeks

  2. Skin hydration

    Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12.

    Time frame: from baseline to 12 weeks

  3. Objective skin-health

    Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12.

    Time frame: from baseline to 12 weeks

07

Study locations

1 site
  • Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork
    Cork, Ireland
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jul 2023, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Apr 7, 2023
StartActual
Dec 12, 2022
Primary completionActual
Jul 6, 2023
CompletionActual
Jul 6, 2023
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited
What changed in the outcomes
  • EditedFaecal microbial composition and diversityTime frame: from baseline to 12 weeks
Nov 10, 2026
Secondary outcomes
2 edited, 1 time frame changed, 6 added, 2 description edited
What changed in the outcomes
  • EditedFaecal physiological pH and redoxTime frame: from baseline to 12 weeks
  • EditedFaecal microbial composition and diversity at week 4Time frame: from baseline to 4 weeks
  • AddedAlpha diversityTime frame: from baseline to 12 weeks
  • AddedBeta diversityTime frame: week 0 to week 12
  • AddedAcetate, Propionate and ButyrateTime frame: baseline and week 12
  • AddedAlpha diversity at week 4Time frame: baseline to Week 4.
  • AddedBeta diversity at week 4Time frame: week 0 to week 4
  • AddedAcetate, Propionate and Butyrate at week 4Time frame: week 0 to week 4
  • Time frameFaecal microbial metabolites fatty acid content at baseline and week 12Intestinal inflammation as assessed by faecal calprotectin at baseline and at week 12 → from baseline to 12 weeks
  • DescriptionFaecal microbial metabolites fatty acid content at baseline and week 12: how it is measured was reworded
  • DescriptionMicrobial metabolites at week 4: how it is measured was reworded
Nov 10, 2026
Sponsor
DSM Nutritional Products, Inc.→dsm-firmenich Switzerland AG
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedFaecal microbial composition and diversityTime frame: from baseline to 12 weeks
    Secondary outcomes 2 edited, 1 time frame changed, 6 added, 2 description edited
    What changed in the outcomes
    • EditedFaecal physiological pH and redoxTime frame: from baseline to 12 weeks
    • EditedFaecal microbial composition and diversity at week 4Time frame: from baseline to 4 weeks
    • AddedAlpha diversityTime frame: from baseline to 12 weeks
    • AddedBeta diversityTime frame: week 0 to week 12
    • AddedAcetate, Propionate and ButyrateTime frame: baseline and week 12
    • AddedAlpha diversity at week 4Time frame: baseline to Week 4.
    • AddedBeta diversity at week 4Time frame: week 0 to week 4
    • AddedAcetate, Propionate and Butyrate at week 4Time frame: week 0 to week 4
    • Time frameFaecal microbial metabolites fatty acid content at baseline and week 12Intestinal inflammation as assessed by faecal calprotectin at baseline and at week 12 → from baseline to 12 weeks
    • DescriptionFaecal microbial metabolites fatty acid content at baseline and week 12: how it is measured was reworded
    • DescriptionMicrobial metabolites at week 4: how it is measured was reworded
    Sponsor DSM Nutritional Products, Inc.→dsm-firmenich Switzerland AG
    + 3 other changes: identifiers, oversight details and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05803811
Collaborators
Atlantia Food Clinical Trials
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Dec 12, 2022
Primary completion
Jul 6, 2023
Completion
Jul 6, 2023
Last update
Nov 10, 2026

Study contacts

Prof Timothy Dinan
principal investigator · Cork University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riboflavin

Start the discussion